Laxenaire M C
Département d'anesthésie-réanimation, hôpital Central, Nancy, France.
Ann Fr Anesth Reanim. 1999 Aug;18(7):796-809. doi: 10.1016/s0750-7658(00)88460-9.
Since 1984 an epidemiological survey of anaphylactoid reactions occurring during anaesthesia has been obtained in France with regular repeated inquiries by the Perioperative Anaphylactoid Reactions Study Group (Gerap). The members of this group collected during the study period cases of patients having suffered from an anaphylactoid reaction and subsequently tested in their allergoanaesthetic outpatient clinic. The three previous surveys published in the Annales françaises d'anesthésie et de réanimation in 1990, 1993 (in English) and 1996 included 1,240, 1,585 and 1,730 patients respectively. The current survey concerned 1,648 patients, tested by the GERAP (38 diagnostic centres) from July 1994 to December 1996. The diagnostic tests for IgE anaphylaxis were cutaneous tests (prick tests and intradermal tests), which minimal dilutions for specific positive skin test were previously determined by comparison with control subjects. The cutaneous tests were performed by all the centres. These tests were associated, in 29 centres, with the detection of specific IgEs against quaternary ammonium compound and inhibition test, and detection of IgEs against propofol, thiopental and latex. Moreover, leukocyte histamine release test was performed in seven centres. The mechanism of the reaction was: anaphylaxis in 692 patients (characteristic clinical symptoms and positive allergological tests), anaphylactoid reactions in 611 patients (characteristic clinical symptoms and negative allergological tests), and other causes in 345 patients (unusual clinical symptoms and negative allergological tests). An immune mechanism was found in 53% of the reactions, with characteristic clinical symptoms occurring during anaesthesia. The 692 cases of anaphylaxis were due to 734 substances (double anaphylaxis in 42 patients): muscle relaxants (61.6%), latex (16.6%), antibiotics (8.3%), hypnotics (5.1%), colloids (3.1%), opioids (2.7%) and others (2.6%) among which aprotinin (four cases) ethylene oxide (five cases) local anaesthetics (two cases). The muscle relaxants implicated in anaphylactic reactions included: vecuronium (n = 130), atracurium (n = 107), suxamethonium (n = 106), pancuronium (n = 41), rocuronium (n = 41), mivacurium (n = 18), and gallamine (n = 9). These results reflected French anaesthetic practice, except for suxamethonium (5% of the French market share of curares). In 70% of the patients who were allergic to one muscle relaxant, cross-sensitivity was found with the other relaxants. The comparison with the three previous surveys confirms that the mechanism of about half of the anaphylatoid reactions occurring during anaesthesia is of immune origin, due to specific IgE antibodies. Muscle relaxants remain the most common cause of anaphylaxis, followed by latex whose incidence seems to decrease, whereas the incidence of anaphylaxis to antibiotics increases. Incidence of reactions to suxamethonium decreased, corresponding however to one quarter of all muscle relaxant anaphylaxis, similar with vecuronium and atracurium. For this survey, more clinical information was obtained in 583 patients, allowing the following conclusions: reactions were always more severe in case of anaphylaxis than nonspecific histamine release; reactions occurred more frequently in females (F/M = 2.5); 17% of patients allergic to a muscle relaxant were never anaesthetized beforehand; a history of reactions during previous anaesthetics was a risk factor for a reaction during subsequent anaesthetics; neither drug allergy nor atopy (except for latex allergy) were a predisposing factor for reactions with anaesthetic agents. Considering that in 1996, 8 million anaesthetics were administered in France, of which 2.5 million included the use of muscle relaxants, the overall incidence for anaphylactic reactions, all agents included, was evaluated as 1 in 13,000 anaesthetics, while the incidence of anaphylaxis to muscle relaxants was 1 in 6,500 anaesthetics.
自1984年以来,法国围手术期类过敏反应研究小组(Gerap)通过定期反复问询,开展了一项关于麻醉期间发生类过敏反应的流行病学调查。该小组的成员在研究期间收集了发生类过敏反应的患者病例,并随后在他们的变态反应麻醉门诊进行检测。之前发表于1990年、1993年(英文)和1996年的《法国麻醉与复苏年鉴》上的三项调查分别涵盖了1240例、1585例和1730例患者。本次调查涉及1994年7月至1996年12月期间由GERAP(38个诊断中心)检测的1648例患者。IgE介导的过敏反应的诊断检测为皮肤试验(点刺试验和皮内试验),之前通过与对照受试者比较确定了特异性阳性皮肤试验的最小稀释度。所有中心均进行了皮肤试验。在29个中心,这些试验与针对季铵化合物的特异性IgE检测、抑制试验以及针对丙泊酚、硫喷妥钠和乳胶的IgE检测相关联。此外,七个中心进行了白细胞组胺释放试验。反应机制为:692例患者为过敏反应(典型临床症状和变态反应学检测阳性),611例患者为类过敏反应(典型临床症状和变态反应学检测阴性),345例患者为其他原因(不寻常临床症状和变态反应学检测阴性)。53%的反应发现存在免疫机制,在麻醉期间出现典型临床症状。692例过敏反应病例归因于734种物质(42例患者为双重过敏反应):肌肉松弛剂(61.6%)、乳胶(16.6%)、抗生素(8.3%)、催眠药(5.1%)、胶体(3.1%)、阿片类药物(2.7%)以及其他(2.6%),其中包括抑肽酶(4例)、环氧乙烷(5例)、局部麻醉药(2例)。与过敏反应相关的肌肉松弛剂包括:维库溴铵(n = 130)、阿曲库铵(n = 107)、琥珀胆碱(n = 106)、泮库溴铵(n = 41)、罗库溴铵(n = 41)、米库氯铵(n = 18)和加拉明(n = 9)。这些结果反映了法国的麻醉实践情况,但琥珀胆碱除外(其在法国箭毒市场份额中占5%)。在对一种肌肉松弛剂过敏的患者中,70%发现对其他松弛剂存在交叉敏感性。与之前的三项调查相比,证实了麻醉期间约一半的类过敏反应机制源于免疫,由特异性IgE抗体引起。肌肉松弛剂仍然是过敏反应最常见的原因,其次是乳胶,其发生率似乎在下降,而抗生素过敏反应的发生率在增加。琥珀胆碱反应的发生率下降,但占所有肌肉松弛剂过敏反应的四分之一,与维库溴铵和阿曲库铵相似。对于本次调查,在583例患者中获取了更多临床信息,得出以下结论:过敏反应的症状总是比非特异性组胺释放更严重;女性反应更频繁(女性/男性 = 2.5);17%对肌肉松弛剂过敏的患者此前从未接受过麻醉;既往麻醉期间有反应史是后续麻醉期间发生反应的危险因素;药物过敏和特应性(乳胶过敏除外)均不是麻醉剂反应的诱发因素。考虑到1996年法国实施了800万例麻醉,其中250万例使用了肌肉松弛剂,所有药物引起的过敏反应总体发生率估计为每13,000例麻醉中有1例,而肌肉松弛剂过敏反应的发生率为每6500例麻醉中有1例。